

Inflammation induced epigenetic activation of bivalent genes in osteoarthritic cartilage

Running title: Epigenetic basis for osteoarthritis

Character count **47,760**

Character count (including spaces) **56,184**

Authors

Hao Du^{1, †}, Yao Zhang^{1, †}, Xi Yu^{1, 2}, Xuanhe You¹, Diwei Wu¹, Zhenyu Luo¹, Yongrui Cai¹, Hanpeng Lu¹, Zhixin Liao¹, Bi-Sen Ding³, Ya Zhao^{4, 5}, Yan Wang^{6, 7}, Ke Xiao⁸, Fan Yang⁹, Fangji Gan¹⁰, Ning Ning¹, Jiancheng Zeng¹, Zongke Zhou^{1, *} & Shishu Huang^{1, *}

Affiliations

1. Department of Orthopedic Surgery and Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.

2. Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, PR China.

3. Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, Chengdu 610041, China.

4. Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225001, PR China;

5. Jiangsu Key Laboratory of Experimental & Translational Non-coding RNA Research, Yangzhou, 225001, PR China

6. College of Animal Science and Technology, Sichuan Agricultural University, Chengdu 611130, China

7. Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, China

8. The lower limb department of Sichuan Province Orthopedic Hospital, the central laboratory of Sichuan Province Orthopedic Hospital, Chengdu, China

9. The Brain Cognition and Brain Disease Institute (BCBDI), Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences (CAS), Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.

10. School of Mechanical Engineering, Sichuan University, Chengdu 610065, China.

† These authors contributed equally to this work.

Corresponding author. Email: h0794062@scu.edu.cn (S.H.); zongke@126.com (Z.Z.)

Abstract

Osteoarthritis (OA) is the most prevalent joint disorder occurring with articular cartilage degradation, which includes a switch from an articular to a growth-plate chondrocyte phenotype. Epigenetics serves as a new therapeutic target but histone modification changes in OA remain elusive. Here, we investigated the profiles of four histone modifications in normal and OA chondrocytes. The repressive mark H3K27me3 was significantly lost in OA, associated with up-regulated gene expression. Surprisingly,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

44 many of these genes were occupied by both H3K27me3 and H3K4me3 in normal
45 chondrocytes, showing a poised bivalent state. These bivalent genes are deemed to be
46 activated during the hypertrophy of growth plate chondrocytes. Furthermore,
47 inflammation induced the expression of demethylase KDM6B and decreased
48 H3K27me3 level in OA chondrocytes, which was rescued by the KDM6B inhibitor
49 GSK-J4. Altogether, our results suggest an inherited bivalent epigenetic signature on
50 developmental genes that makes articular chondrocytes prone to hypertrophy and
51 contribute to a promising epigenetic therapy for OA.

52

53 **Key words:** Osteoarthritis; Epigenetics; Histone modification; Chondrocyte hypertrophy

54

55 **The Paper Explained**

56 **Problem**

57 Osteoarthritis (OA) affects as much as 40% of the elderly population, representing the largest
58 cause of age-related disability. The high susceptibility to OA suggests an intrinsic and systemic
59 characteristic in articular chondrocytes that makes cartilage prone to degeneration.

60 **Results**

61 Epigenetic bivalent genes, which are occupied with both H3K27me3 and H3K4me3, are
62 considered to poise expression of developmental genes. Surprisingly, we reported bivalency for
63 hypertrophy related genes in normal articular chondrocytes. These bivalent genes need to be
64 activated in growth plate chondrocytes for extracellular matrix degradation and ossification, but
65 are left as a “bomb” for degeneration in articular chondrocytes. We further found that
66 inflammation induced KDM6B remove H3K27me3 to activate hypertrophy related genes that
67 promote OA.

68 **Impact**

69 Our results suggest an inherited epigenetic signature that makes articular chondrocytes prone to
70 hypertrophy and ossification and contribute to a promising epigenetic therapy for OA.

71

72 **Introduction**

73 Osteoarthritis (OA) is one of the most prevalent joint disorders that affects an estimated
74 300 million adults worldwide (Vos *et al*, 2017). OA is mainly characterized by chronic
75 joint pain caused by the degradation of articular cartilage and inflammation of the
76 synovium, which would induce age-related disability eventually. Current standard
77 therapies for OA are limited, including pain amelioration and eventual total joint
78 replacement (Bannuru *et al*, 2019), which do not prevent or restrain the loss of cartilage.

79 Up to date, many therapeutic strategies have focused on molecular pathways that are
80 deregulated in OA. The relevant drugs include metalloproteinase and aggrecanase
81 inhibitors to target catabolic enzymes responsible for degradation of articular cartilage,
82 bisphosphonates and antiresorptive drugs to stabilize bone homeostasis, inducible nitric
83 oxide synthase (iNOS) and NF- κ B inhibitors to target inflammatory pathways (Karsdal
84 *et al*, 2016). These drugs, however, have had limited preclinical and clinical success
85 (Karsdal *et al*, 2016). One possible reason is that OA is a disease of complex pathology
86 which involves multiple signaling pathways and these drugs target single molecular
87 pathway only. In fact, most risk factors of OA, including aging, obesity, trauma and
88 biomechanics, have been associated to epigenetic changes (Yang *et al*, 2021; Zhang *et al*,
89 2020; Ling & Rönn, 2019). Interestingly, epigenetic regulations can act on multiple
90 gene programs at the same time, thus having the potential to reprogram the aberrant state

91 of the cell. However, it is unknown whether epigenetic changes may play a common
92 pathogenic role in the development of OA. As such, it is worth investigating epigenetic
93 changes associated with OA, their potential impact on OA-associated gene expression,
94 and disease pathology.

95 Epigenetics is defined as the changes ‘on top of’ (epi) the genome that influence the
96 transcription of genes, which mainly imply DNA methylation and various histone
97 modifications. Multiple studies have mapped global DNA methylation changes
98 associated with OA (Taylor *et al*, 2015; Reynard, 2017) and provide an attractive
99 therapeutic strategy (Smeriglio *et al*, 2020). Compared to DNA methylation, histone
100 modifications are more diverse, complex and have close interactions with the former,
101 providing broader therapeutic prospect (Grandi & Bhutani, 2020).

102 Histones are subject to post-translational modifications that include methylation,
103 acetylation, phosphorylation and ubiquitylation, among others (Millán-Zambrano *et al*,
104 2022). Different histone modifications occupy distinct positions on the genome and
105 confer distinct active or repressive transcription effect (Hyun *et al*, 2017). Histone 3
106 lysine 4 trimethylation (H3K4me3) marks active transcription and is highly enriched at
107 the promoter region and transcription start site. H3K27me3 is a hallmark of
108 transcriptional repression. H3K9me3 is a well-known indicator of silenced transcription
109 and heterochromatin structure. Acetylation of H3K27 (H3K27ac) is the best-known
110 epigenetic mark for active enhancers and also enriched in highly expressed genes.
111 Promisingly, plenty of studies have revealed the involvement of histone modification
112 enzymes in cartilage development and pathology (Dudakovic *et al*, 2015, 2; Camilleri
113 *et al*, 2018, 2; Du *et al*, 2020, 2; Zhang *et al*, 2015, 3; Dai *et al*, 2017, 6; Monteagudo *et al*,
114 2017). While genome-wide changes of histone modifications associated with OA are
115 still unknown.

116 In this study, we compared the genome-wide profiles of classic histone modifications in
117 normal and OA chondrocytes and identified a significant decrease of repressive mark
118 H3K27me3 in OA. This H3K27me3 loss derepressed gene expression, especially of
119 bivalent genes, which are occupied by both H3K27me3 and H3K4me3. Interestingly,
120 these genes are deemed to be activated during developmental chondrocyte hypertrophy.
121 Further investigation revealed that inflammation induced histone demethylase KDM6B
122 lead to H3K27me3 loss and can be an attractive therapeutic target for OA.

123

124 **Results**

125 **The profiling of histone modifications in normal and OA chondrocytes**

126 To gain a comprehensive view of the histone modification landscape in human articular
127 chondrocytes and identify epigenetic changes associated with OA, we performed
128 CUT&Tag and RNA-seq in normal and OA chondrocytes (Fig 1A). Two pairs of OA-
129 Intact/Damaged samples were also included. OA-Intact cartilage showed slightly uneven
130 surface compared to normal cartilage, whereas OA-Damaged cartilage exhibited severe
131 erosion (Fig EV1A). We investigated the distribution of the activating promoter mark
132 H3K4me3, the repressive mark H3K27me3, the promoter and enhancer mark H3K27ac,
133 and the heterochromatin mark H3K9me3.

134 We first examined the tag density of each chromatin mark in genes. H3K4me3 and
135 H3K27ac were highly enriched at the transcription start site (TSS) (Fig 1B and Fig
136 EV1B). H3K27me3 were enriched at promoters and showed broader distribution than
137 H3K4me3. Surprisingly, OA samples showed overall lower H3K27me3 compared to
138 Normal (Fig 1B). The heterochromatin mark H3K9me3 showed low tag density on gene
139 bodies in all samples. Subsequently, we used SEACR (Sparse Enrichment Analysis for
140 CUT&RUN) script to identify genomic regions enriched for each chromatin mark.
141 About 20000 peaks were obtained for each group (Fig 1C) and 10000~20000 peaks for
142 each sample (Fig EV1C). The genome-wide peak distribution varied among different
143 modifications but showed no significant difference in the four groups (Fig 1C). For
144 H3K4me3, H3K27me3 and H3K27ac, most peaks were located in promoters and gene
145 bodies. H3K9me3 peaks mainly located in intergenic regions and gene bodies (Fig 1C).
146 The expected distribution of the four marks illustrated the reliance of our CUT&Tag
147 experimental procedure.

148 As OA exhibited lower H3K27me3 in genes than Normal (Fig 1B), we wondered
149 whether this change reflects an overall decrease or was restricted to a group of genes. To
150 elucidate genes with differential H3K27me3 and other histone marks, we calculated
151 peak strength that locate in each gene (TSS +/-2kb). Indeed, about 7000 genes were
152 identified to have differential H3K27me3 strength in OA versus Normal, with more than
153 5000 genes lost H3K27me3 in OA (Fig 1D). Surprisingly, in Damaged versus Intact,
154 over 1000 genes lost H3K27me3 and very few genes gain H3K27me3 (Fig 1D), in
155 accordance with the overall decrease in tag density (Fig 1B). The dominance of
156 H3K27me3 down-regulated genes in both compares indicated the importance of this
157 H3K27me3 loss. Furthermore, the majority of genes that were found to lose H3K27me3
158 in Damaged versus Intact were also found in OA versus Normal (Fig 1E). These genes
159 gradually lost H3K27me3 from Normal to OA-Intact to OA-Damaged (Fig 1F). For
160 H3K4me3, more than 7000 genes showed a decrease in OA versus Normal, and over
161 1000 genes showed a decrease in Damaged versus Intact (Fig 1D and Fig EV2A).
162 However, the decrease of H3K4me3 was weaker than H3K27me3 (Fig 1F and Fig
163 EV2B). For H3K27ac and H3K9me3, relatively few differential genes were found in OA
164 versus Normal (Fig 1D).

165 As the histone modification peaks, especially H3K9me3, also distributed in intergenic
166 regions (Fig 1C), peaks outside genes with differential strength were calculated between
167 OA and Normal, Damaged and Intact (Fig 1G). However, few differential H3K9me3
168 peaks were found in both compares. Surprisingly, most differential H3K4me3 peaks
169 outside genes were up-regulated, in both OA versus Normal and Damaged versus Intact
170 (Fig 1, G and H). Moreover, the up-regulated H3K4me3 peaks were enriched around
171 centromere (Fig EV2C), while H3K27me3 didn't show similar pattern (Fig EV2D),
172 which needs further exploration.

173 Genome-wide correlation among all samples suggested that H3K27me3 was more
174 effective than the other three marks to distinguish between OA and Normal (Fig EV3).

175 **Correlation between H3K27me3 loss and gene up-regulation in OA**

176 To correlate histone modification to gene expression, transcriptomes of the
177 corresponding samples were analyzed (Fig 2A). In OA versus Normal, 583 genes were
178 down-regulated, and 297 genes were up-regulated. In Damaged versus Intact, 1327

179 genes were down-regulated, and 657 genes were up-regulated. First, we plotted the RNA
180 expression levels against the modification levels in genes for normal samples (Fig 2B).
181 This analysis indicated that gene expression positively correlated with H3K4me3 and
182 H3K27ac in chondrocytes. The repressive mark H3K27me3 were associated with genes
183 expressed at low levels and negatively correlated with the expression levels. The
184 expected correlations further proved the reliability of our methods.

185 To elucidate the correlation between modification and gene expression changes, the
186 RNA expression fold changes were plotted against the histone modification fold changes
187 in OA versus Normal and Damaged versus Intact (Fig 2C). The H3K27me3
188 modification changes inversely correlated with gene expression changes, and H3K27ac
189 positively correlated with gene expression. H3K4me3 changes positively correlated with
190 expression changes in Damaged versus Intact, but not in OA versus Normal. Overall,
191 OA samples exhibited strongest correlation between decreased H3K27me3 and up-
192 regulated gene expression (Fig 2C), consistent with the significant H3K27me3 loss in
193 OA (Fig 1, D and F).

194 Additionally, we investigated the changes of histone modifications in up or down-
195 regulated gene groups (Fig 2D). Surprisingly, H3K27me3 decreased markedly in up-
196 regulated genes in both OA versus Normal and Damaged versus Intact, and H3K4me3
197 and H3K27ac level showed no significant change. This phenomenon indicated that the
198 gene up-regulation in OA mainly depends on the removal of repressive mark H3K27me3
199 rather than the addition of activating marks. For the down-regulated genes, H3K27ac
200 exhibited moderate decrease in both OA versus Normal and Damaged versus Intact (Fig
201 2D). Repressive mark H3K27me3 showed a slight decrease in OA versus Normal, which
202 may result from the global H3K27me3 loss in OA (Fig 1, B and D). H3K4me3 showed a
203 slight decrease in both down-regulated and up-regulated genes in OA versus Normal.
204 This reflected an overall slight decrease of H3K4me3 (Fig 1D and Fig EV2B), which did
205 not affect gene expression. Specifically, 443 genes were identified to lose H3K27me3
206 and gain expression in OA versus Normal, with 328 genes in Damaged versus Intact,
207 and 128 genes in both compared groups (Fig 2E). The overlapped genes were highly
208 enriched in GO terms like inflammatory signaling and extracellular matrix organization
209 (Fig 2F), which are among the most typical changes in OA pathology, suggesting
210 biological significance of H3K27me3 loss-mediated gene derepression in OA.

211 **H3K27me3 loss mediated up-regulation mainly occur on bivalent genes**

212 As previously discovered, thousands of genes lost H3K27me3 in OA (Fig 1D) but only
213 hundreds of them were up-regulated (Fig 2E). We wondered whether other histone
214 marks contribute to this difference. Accordingly, we defined 12 chromatin states
215 carrying distinct combinations of the four histone marks using ChromHMM (Ernst &
216 Kellis, 2017) (Fig 3A). The enrichment of these chromatin states was examined at global
217 level and in specific genomic features in three normal samples (Fig EV4A). Genome-
218 wide correlation of chromatin states among all samples suggested better discrimination
219 between Normal and OA samples than each single histone mark (Fig EV4B and S3).
220 Then we defined the promoter state of each gene by the chromatin states of 2kb region
221 around TSS (Fig 3B). The most prevalent promoter state was empty (state 12, 3) which
222 include about 20000 genes in Normal. Other promoter states were activating (states 9,
223 10, 11), repressive (states 5, 6, 7) and bivalent (state 8). H3K27me3 exist in states 5, 6, 7
224 and 8. Surprisingly, genes with bivalent promoters (state 8) account for more than 2000

225 in Normal and decreased by half in OA (Fig 3B). As bivalent domains are well known in
226 embryonic stem cells but not in terminal-differentiated cells, we wondered whether the
227 observed bivalency came from mixed populations of cells that carry either repressive or
228 activating marks at a given locus. However, the very low expression level of these genes
229 in normal chondrocytes (Fig 3I) didn't support the exist of activating cell population.
230 Although terminally differentiated, normal articular chondrocytes still harbored plenty of
231 bivalent genes.

232 To find out if the loss of H2K27me3 has preference for bivalent promoters, we looked
233 into the promoter states of about 5000 genes that lost H3K27me3 in OA versus Normal
234 (Fig 1D). However, both bivalent (state 8) and repressive (state 6) genes exhibited
235 significant enrichment in Normal (Fig 3C), with about a half of all genes in each state
236 lost H3K27me3. Accordingly, genes in state 8 and 6 decreased significantly from
237 Normal to OA (Fig 3C). Genes in state 9 and 7 increased in OA, which may result from
238 the loss of H3K27me3 in state 8 and 6. Next we plotted the Log₂ fold change of
239 H3K27me3 in OA versus Normal for genes in states 5 to 8 (Fig 3D). Interestingly, genes
240 in state 8 showed significantly more H3K27me3 down-regulation than other three
241 groups. What's more, the overall gene expression level of state 8 exhibited a significant
242 up-regulation from Normal to OA, whereas genes in state 5-7 did not express in both
243 Normal and OA (Fig 3E). These results suggested that H3K27me3 loss occurred mainly
244 on genes of state 8 and 6. While only state 8, namely bivalent genes, resulted in the up-
245 regulation of gene expression, which may due to the pre-exist of activating mark
246 H3K4me3.

247 Next, we want to know the contribution of bivalent genes de-repression on the overall
248 gene up-regulation. Among the 297 genes that up-regulated in OA versus Normal, genes
249 with primed promoter (state 9) account for the largest proportion (Fig 3F). However,
250 genes with active promoter (state 10) showed no increase in OA, we assumed that these
251 genes used other transcriptional or post-transcriptional mechanism to increase
252 expression level. Importantly, the most significant state change from Normal to OA is
253 the loss of bivalent genes and increase of primed genes (Fig 3F).

254 State transition analysis verified the transition from bivalent genes in Normal to primed
255 genes in OA (Fig 3G, state 8 to 9). Other obvious transitions include state 6 to 7, 7 to 12
256 and 5 to 2, which all attributed to the loss of H3K27me3. However, some bivalent genes
257 also lost H3K4me3 to become repression (state 6).

258 **Bivalent genes derepression in OA resembles growth plate chondrocytes** 259 **hypertrophy**

260 We further analyzed states transitions of the 2346 bivalent genes in each sample (Fig
261 3H). A lot of bivalent genes lost H3K27me3 or H3K4me3 in OA. Especially, some OA
262 samples exhibited an overall H3K27me3 loss (O28, O27-Dam). Paired samples also
263 showed more H3K27me3 loss in Dam versus Int. Bivalent genes lost H3K27me3 in OA
264 are enriched in GO terms that include cell migration, extracellular matrix organization,
265 Wnt signaling pathway and ion transport (Fig 3I). Bivalent domains are deemed to poise
266 developmental genes for future activation, whereas articular chondrocytes are meant to
267 persist to form permanent cartilage. Originating from the same cartilage mass, growth
268 plate chondrocytes undergo proliferation, hypertrophy and apoptosis, which promotes
269 degradation and calcification of cartilage matrix to drive bone growth. OA pathogenesis

270 commonly includes a switch from the articular to the growth plate chondrocyte
271 phenotype, and re-initiation of proliferation and hypertrophy (Pitsillides & Beier, 2011).

272 We wondered whether the bivalent genes need to be activated during the proliferation
273 and hypertrophy of growth plate chondrocytes but remain as a developmental legacy
274 feature in articular chondrocytes. Re-analysis of the epigenetic data from a mouse study
275 (Wuelling *et al*, 2021) revealed 162 bivalent genes in proliferating chondrocytes that lost
276 H3K27me3 in hypertrophic chondrocytes (Fig EV4, C to E) (Table S3). GO analysis
277 revealed enrichment in several terms like multicellular organism development and ion
278 transport (Fig 3I). Overlapping GO terms between OA and growth plate chondrocytes
279 hypertrophy suggested the similarity between the two process.

280 Next, we defined the bivalent genes that lose H3K27me3 or H3K4me3 in OA versus
281 Normal and Damaged versus Intact. Apparently, the vast majority of the altered bivalent
282 genes lose H3K27me3 and only a very small number lose H3K4me3 (Fig 3J).
283 Furthermore, the bivalent genes lost H3K27me3 tend to obtain higher expression level in
284 both OA versus Normal and Damaged versus Intact (Fig 3, J and K). Typical bivalent
285 genes that lose H3K27me3 and gain expression in OA were shown (Fig 3L). These data
286 suggest that H3K27me3 loss in bivalent promoters up-regulate gene expression in OA
287 articular chondrocytes, which is consistent to the hypertrophy and ossification of growth
288 plate chondrocytes.

289 **Inflammation induced H3K27 demethylase expression in OA chondrocytes**

290 Next, we wondered what caused the loss of H3K27me3 on bivalent promoters in OA.
291 H3K27me3 are added by the PRC2 complex that consist EZH1/2, EED and SUZ12, and
292 removed by KDM6A and KDM6B (Xiang *et al*, 2007; Hong *et al*, 2007; Agger *et al*,
293 2007; De Santa *et al*, 2007). However, the RNA expression of these methyltransferases
294 and demethylases in our RNA-seq dataset showed no significant difference in OA versus
295 Normal and Damaged versus Intact (Fig EV5). Inflammation plays an important role in
296 the development of OA. Proinflammatory cytokines like IL-1 β downregulate the
297 synthesis of major extracellular matrix (ECM) components and induce the production of
298 proteolytic enzymes of chondrocytes. Thus, IL-1 β is widely used to create a cellular
299 model of OA. Interestingly, IL-1 β treatment increased the expression of H3K27me3
300 demethylases in human chondrocytes from OA patients (Fig 4A), with a higher
301 induction ratio of KDM6B than KDM6A. It has been reported that KDM6B (JMJD3)
302 contributes to the control of gene expression in LPS-activated macrophages (De Santa *et al*
303 *et al*, 2007, 2009) and is involved in inflammatory diseases. More importantly, KDM6B
304 has been reported to promote chondrocyte proliferation and hypertrophy in endochondral
305 bone formation (Zhang *et al*, 2015, 3). These results suggested KDM6B as a candidate
306 for H3K27me3 loss in OA. However, KDM6B showed no statistic difference in human
307 normal and OA cartilage by immunofluorescence (IF) staining (Fig 4, B and C), in
308 which KDM6B positive cells were around 50% in both groups. However, acute
309 inflammation is contraindicated for knee replacement. So, the OA cartilage samples we
310 collected here were inflammation quiescent and may not exhibit KDM6B up-regulation.
311 A time course that simulating the transient inflammation in OA patients detected the fall
312 back of KDM6B after IL-1 β removal (Fig 4D). We then established a rat surgical
313 instability OA model to examine KDM6B in cartilage and synovial inflammation by
314 *H&E* staining. OA synovium exhibited typical hyperplasia and plenty of inflammatory
315 cells in both 4w and 8w (Fig 4E). Interestingly, KDM6B positive cells raised from

316 sporadic in shame to about 50% in OA (Fig 4F). These data suggest that inflammation
317 induces the expression of KDM6B, which may be responsible for the H3K27me3 loss in
318 OA chondrocytes.

319 **KDM6 inhibitor rescued inflammation-induced H3K27me3 loss and abnormal gene** 320 **expression**

321 We tested whether the inflammation induction of KDM6B causes H3K27me3 loss in
322 human OA chondrocytes by CUT&Tag. It was found that IL-1 β treatment resulted in a
323 significant H3K27me3 decrease across gene bodies on the whole genome (Fig 5A).
324 Interestingly, 48hr after the withdraw of IL-1 β , with the expression level of KDM6B fell
325 back (Fig 4D), the H3K27me3 level didn't recover. This may explain the contradiction
326 of H3K27me3 loss and normal KDM6B level in OA patients (Fig 4, B and C). Acute
327 inflammation in OA patients induce the transient expression of KDM6B, which may
328 result in H3K27me3 loss that could persist even after the acute inflammation.

329 To verify the importance of KDM6B in this process, we used a selective KDM6
330 inhibitor, GSK-J4 (Kruidenier *et al*, 2012). Surprisingly, combined utilization of GSK-J4
331 and IL-1 β completely inhibited this H3K27me3 loss (Fig 5B). 3661 genes were
332 identified to lose H3K27me3 upon IL-1 β and simultaneously rescued by GSK-J4, which
333 contain 569 genes of the previously found 728 genes that lose H3K27me3 in OA versus
334 Normal and Damaged versus Intact (Fig 5C). Furthermore, the overlapped 569 genes
335 showed higher H3K27me3 in control and GSK-J4 rescued samples than the rest 3092
336 genes (Fig 5D), suggesting the consistence between *in vivo* and *in vitro* conditions.
337 Typical genes that lost H3K27me3 upon IL-1 β and restored H3K27me3 by GSK-J4
338 were shown (Fig 5E). Accordingly, their gene expression level increased upon IL-1 β and
339 were repressed by GSK-J4 (Fig 5F). Therefore, a key role of KDM6B was proposed in
340 inflammation induced H3K27me3 loss and abnormal gene expression in OA
341 chondrocytes (Fig 6).

342 Altogether, our data revealed the loss of H3K27me3 and de-repression of bivalent genes
343 that caused chondrocyte hypertrophy in OA. Inflammation induced the expression of the
344 H3K27me3 demethylase KDM6B, thus provides epigenetic mechanism for IL-1 β
345 induced cartilage destruction.

346 **Discussion**

348 Our study, for the first time, provides a genome-wide histone modification map for OA
349 chondrocytes. The most significant change in OA is the loss of repressive mark
350 H3K27me3 on promoters, which in turn lead to up-regulation of OA related genes.
351 Surprisingly, in normal chondrocytes plenty of genes are bivalent, allowing easily
352 activation upon H3K27me3 loss in OA, which resemble hypertrophy related genes in
353 growth plate chondrocytes. This finding provides novel epigenetic evidence for the
354 developmental explanation for OA. Further investigation revealed that H3K27me3
355 demethylase KDM6B is highly expressed in a rat OA model and also induced by IL-1 β
356 in human OA chondrocytes. IL-1 β treatment leads to significant H3K27me3 loss and up-
357 regulation of OA related genes. While a KDM6B inhibitor, GSK-J4, fully restores
358 H3K27me3 and partially down-regulates gene expression, which serves as an attractive
359 therapeutic strategy for OA.

360 Several studies have addressed the importance of H3K27me3 methyltransferases and
361 demethylases in cartilage development and OA. Loss of PRC2 components Ezh2 or Eed
362 in murine chondrocytes accelerate hypertrophic differentiation and stimulates an
363 osteogenic transcriptional program (Camilleri *et al*, 2018, 2; Mirzamohammadi *et al*,
364 2016), highlighting the importance of H3K27me3 in suppressing Wnt and TGF- β
365 signaling. Another study found that EZH2 was highly expressed in a subpopulation of
366 OA patients and ameliorates OA by inhibiting hypertrophy (Du *et al*, 2020, 2),
367 consistent with our findings. Before the finding in endochondral bone formation (Zhang
368 *et al*, 2015, 3), KDM6B is known to be an inducible enzyme that plays key roles in
369 development (Agger *et al*, 2007; Estarás *et al*, 2012) and inflammatory response (De
370 Santa *et al*, 2007, 2009). The effect of KDM6B in OA is controversy. One study
371 reported that knockdown of Kdm6b in mouse chondrocytes leads to accelerated OA
372 progression, with the number of Kdm6b-positive chondrocytes lower in both mice and
373 human OA cartilage samples (Dai *et al*, 2017). While other studies reported an increased
374 expression of KDM6B in OA chondrocytes, and GSK-J4 prevented the expression of
375 pro-inflammatory cytokines and catabolic enzymes (Yapp *et al*, 2016, 3; Jun *et al*,
376 2020). Furthermore, the latter study demonstrated a cartilage protection effect of GSK-
377 J4 in a surgically induced mouse OA model (Jun *et al*, 2020).

378 Our research on human OA cartilage samples showed a significant loss of H3K27me3
379 genome-wide and especially on hypertrophic genes, supporting an OA promoting effect
380 for KDM6B. We also found KDM6B up-regulation in a rat OA model and IL-1 β treated
381 human OA chondrocytes, but not in human OA specimen. In addition to the
382 inflammation quiescent explanation we discussed above, another possibility is the
383 dysregulation of cofactors that bring KDM6B to specific genome locus. As GSK-J4 is an
384 inhibitor of both KDM6B and KDM6A, mapping global targets of this two demethylases
385 and putative cofactors in OA cartilage can provide us better insights into the putative
386 candidature of GSK-J4 and related molecules for OA therapeutics. In addition, we found
387 an increase of H3K4me3 in intergenic regions indicating the loss of preciseness in
388 epigenetic regulation that requires further investigation.

389 In this study, we found that inflammation induced KDM6B lead to a significant decrease
390 of H3K27me3 which lead to the activation of bivalent genes in OA. Our results suggest
391 an inherited epigenetic signature that makes articular chondrocytes prone to hypertrophy
392 and ossification and contribute to a promising epigenetic therapy for OA.
393
394

395 **Materials and Methods**

396 **Human articular cartilage samples**

397 Experiments involving human subjects were performed according to the Ethics
398 Committee on Biomedical Research, West China Hospital of Sichuan University.
399 Informed consent was obtained from patients. OA cartilage tissues were obtained from
400 patients undergoing total knee arthroplasty due to end-stage OA at West China Hospital.
401 Normal cartilage tissues were obtained from individuals undergoing amputation (without
402 OA). The whole layer of cartilage from medial and lateral femoral condyle were cut into
403 small pieces and digested by 4mg/ml PRONASE Protease (Millipore, 53702) for 1hr
404 followed by 1mg/ml collagenase (Nordmark, S1746502) in DMEM/F12 with 10% FBS
405 overnight. The dissociated chondrocytes were then used for CUT&Tag and RNA-seq
406 library construction.

407 **CUT&Tag library construction and sequencing**

CUT&Tag libraries were constructed as previously described (Kaya-Okur *et al*, 2020). In brief, chondrocytes were lysed to acquire nuclei and bind to Concanavalin-coated magnetic beads (Polysciences, 86057). Beads were incubated successively with the primary antibody (Anti-H3K4me3, Abcam, ab8580; Anti-H3K27me3, Active motif, 39055; Anti-H3K27ac, Abcam, ab177178; Anti-H3K9me3, Abcam, ab176916), the secondary antibody (Goat Anti-Rabbit IgG(H+L), Abclonal, AS070) and pG-Tn5 (Vazyme, S602) loaded with mosaic-end adapters. Tn5 was activated by addition of Mg²⁺. DNA was released in a small volume of SDS. Samples were enriched by PCR amplification (NEBNext, 2X PCR premix, M0541) followed by magnetic bead cleanup (Vazyme, N411) and sent for paired-end 150-bp sequencing performed on an Illumina HiSeq 2500 platform.

Rat OA model

Experiments involving animal subjects were performed in accordance with Institutional Animal Care and Use Committee (IACUC) of the Sichuan University-approved protocols. Six-week-old male SD rats were purchased from Chengdu Enswille Biotechnology Co., LTD. Two weeks after adaptation, the OA model was established by anterior cruciate ligament transection (ACLT) plus destabilization of the medial meniscus (DMM) under isoflurane anesthesia. Briefly, the skin was cut approximately 2cm along the medial side of the knee joint, and the tissue was subsequently separated until the patellar ligament was exposed. The joint capsule was opened medial to the patellar ligament. After cutting the anterior cruciate ligament, the anterior horn of the medial meniscus was carefully removed along the medial edge of the tibial plateau (sham operation group only opened the joint capsule without other surgery), and finally the joint capsule, muscle and skin were sutured. At four or eighth week after surgery, rats were sacrificed under isoflurane anaesthetization.

Cell culture and treatment

The dissociated chondrocytes were cultured in DMEM/F12 with 2% FBS. For time course that simulating the acute inflammation, 5ng/ml IL-1 β was added for 2days and then removed for another 2 days. For the rescue experiment, 5ng/ml IL-1 β alone or in combination with 5 μ M GSK-J4 (abmole, M5149) were added for 48hrs.

CUT&Tag data processing

Read quality of the raw sequences was verified with fastqc (0.11.9). All sequence reads were then aligned to the hg38 build of the human reference genome by bowtie2 (2.3.5.1) using --end-to-end --very-sensitive --no-mixed --no-discordant --phred33 -I 10 -X 700 parameters. Duplication rate of each sample was checked with Picard tools (2.3.1). Mapped reads were normalized to 1 million to generate histone modification enrichment around genes with deeptools (3.5.1) (Ramírez *et al*, 2016). For H3K4me3, H3K27me3, H3K27ac and H3K9me3, to assess data reproducibility between different samples, correlation analysis of normalized mapped reads counts in each 500-bp bins across the whole genome was calculated.

All CUT&Tag peaks were called by SEACR (1.3) (Meers *et al*, 2019) with parameters 0.01 non stringent. Subsequently, these identified peaks were classified into five categories with the following order: promoter, gene body, enhancer, region 10kb nearby TSS and intergenic region. To calculate the differential peaks of particular histone modification, we combined all the mapped reads of each sample to identify “common” peaks of this histone modification. The tags abundance of each peak in Normal, OA, OA-Int and OA-Dam sample was quantified independently and limma was used for

455 differential expression analysis. The peaks exhibiting tags abundance foldchange >2 or
456 <0.5 and P-value <0.05 over OA to Normal or OA-Dam to OA-Int were defined as up-
457 regulated or down-regulated peaks. To calculate the differential genes of particular
458 histone modification, we calculated the tags abundance on all gene promoters, which
459 were defined as +/- 2kb region around the TSS of each gene, in each sample. The genes
460 exhibiting tags abundance foldchange >2 or <0.5 and P-value <0.05 over OA to Normal
461 or OA-Dam to OA-Int were defined as up-regulated or down-regulated genes. The
462 mapped CUT&Tag reads and identified peaks were visualized on the Integrative
463 Genomics Viewer (IGV).

464 **RNA-seq data processing**

465 Hisat2 (2.1.0) software was used to align the clean sequencing reads to the human
466 reference genome (hg38) with parameters (--no-unal --rna-strandness FR --fr).
467 Expression levels for all genes were quantified to fragments per kilobase million
468 (FPKM) using Stringite (2.2.0) with default parameters. Subsequently, edge R was used
469 for differential expression analysis. The genes with expression level fold change >2 or
470 <0.5 and P-value <0.05 was defined as up-regulated genes or down-regulated genes
471 respectively. Gene Ontology analysis were performed using DAVID (Sherman *et al*,
472 2022).

473 **Histone modifications and its correlation with gene expression**

474 To quantify correlation of histone modification levels with gene expression value, tags
475 in identified peaks which overlapped with gene promoters were summed and normalized
476 for each gene to represent the modification levels. The genes were then ranked and
477 binned by its modification levels. Each bin of genes (100) is represented by a dot on the
478 plot, with the arithmetic mean of histone modification and gene expression levels to
479 stand for the histone modification and gene expression level of the bin.

480 To quantify correlation of histone modification changes with gene expression changes,
481 the modification levels of each gene was also calculated as the same manner. The
482 change of modification level and gene expression level was calculated as the logarithm
483 of the ratio of the normalized modification levels and gene expression levels in OA
484 versus Normal or OA-Dam versus OA-Int. The genes were then ranked and binned by
485 its modification changes, with the average of their expression changes and modification
486 changes to represent one dot in the plot.

487 **Defining epigenetic states with ChromHMM**

488 The mapped CUT&Tag reads were used as input for ChromHMM (1.24) (Ernst &
489 Kellis, 2012). The whole genome was segmented into non-overlapping bins of 200 bp. A
490 multivariate Hidden Markov Model was used to model the combinatorial and spatial
491 patterns from H3K4me3, H3K27me3, H3K27ac and H3K9me3 markers in each bin.
492 Based on their estimated log-likelihoods, the 12-state ChromHMM model was selected.
493 According to the combinatorial patterns of 4 histone markers of each state, we defined
494 these states as H3K9me3-H3K4me3, HeteroChromatin, Empty, Weak HeteroChromatin,
495 Silenced gene, Repression, Weak Repression, Bivalent promoter, Primed promoter,
496 Active promoter, Enhancer and empty. To assess the robustness of trained model
497 between different samples, we used kappa analysis to evaluate the state agreement
498 between Normal, OA, OA-Int and OA-Dam subsets. The fold enrichment of each
499 ChromHMM state was also quantified at Refseq gene, Refseq exon, RefSeq TSS,
500 RefSeq TSS, +/-2kb region around RefSeq TSS and CpG islands.

501 **Analysis of ChromHMM bivalent promoter state transition**

502 For ChromHMM bivalent promoter state transition analysis of Normal to OA and OA-
503 Int to OA-Dam, we calculated the bivalent promoter state occurrence in +/- 1kb region
504 around TSS (10 ChromHMM bins) of each gene. The genes with at least 7 bivalent
505 promoter state in at least 2 of 3 Normal samples was defined as bivalent genes. We then
506 count and plot heatmap to show the occurrence of ChromHMM state transition in +/- 1kb
507 region around TSS of each bivalent gene in OA, OA-Int and OA-Dam subsets. For each
508 bivalent gene, “H3K27me3 loss” was happened in the subset if there was at least 4
509 ChromHMM primed promoter or active promoter state occurred, “H3K4me3 loss” was
510 happened in the subset if there was at least 4 ChromHMM repression state occurred,
511 “bivalent” was happened in the subset if there was still at least 6 ChromHMM bivalent
512 promoter state occurred.

513 To figure out the genes with H3K27me3 loss and H3K4me3 loss in the process of
514 Normal to OA or OA-Int to OA-Dam, we first defined the states transition of each bin
515 according to the occurrence in all samples. The bins with at least 2 ChromHMM primed
516 promoter or active promoter state in 4 OA subsets were defined as H3K27me3 loss bins
517 in OA, the bins with at least 1 ChromHMM primed promoter or active promoter state in
518 2 OA-Int or OA-Dam subsets were defined as H3K27me3 loss bins in OA-Int or OA-
519 Dam, the bins with at least 2 ChromHMM repression state in 4 OA subsets as H3K4me3
520 loss bins in OA, the bins with at least 1 ChromHMM repression state in 2 OA-Int or OA-
521 Dam subsets as H3K4me3 loss bins in OA-Int or OA-Dam. The genes with at least 40%
522 bivalent bins occurred H3K27me3 loss or H3K4me3 loss was defined as H3K27me3
523 loss genes or H3K4me3 loss genes. The expression levels in Normal, OA, OA-Int and
524 OA-Dam and expression changes between them were then counted and plotted.

525 **Statistical analysis**

526 Analyses were performed using GraphPad Prism 9.0 (GraphPad Software, USA). All
527 data were presented as means \pm SDs. Statistical comparisons of two groups were
528 performed by two-tailed ratio paired or unpaired t test. Multiple comparisons were made
529 using ordinary one-way ANOVA followed by Tukey's multiple comparisons test.
530 Statistical significance (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001) was
531 indicated in figures.

532 **Data availability**

533 The CUT&Tag and RNA-seq data generated in this study have been deposited in the
534 NCBI's Sequence Read Archive (SRA) database under accession code PRJNA930583.
535 The mouse PC and HC ChIP-seq data was downloaded through the GEO accession
536 numbers. All code required for data analyses and figure preparation are available at
537 [https://github.com/luciferase1234/Inflammation-induced-epigenetic-activation-of-](https://github.com/luciferase1234/Inflammation-induced-epigenetic-activation-of-bivalent-genes-in-osteoarthritic-cartilage)
538 [bivalent-genes-in-osteoarthritic-cartilage](https://github.com/luciferase1234/Inflammation-induced-epigenetic-activation-of-bivalent-genes-in-osteoarthritic-cartilage). All data are available in the main text or the
539 supplementary materials.
540

541 **Acknowledgments**

542 We are grateful to the IT Center of west china hospital for supplying the computing
543 resources. We thank Professor Hongjie Shen for his advice and criticism. This work was
544 supported by National Natural Science Foundation of China (81874027, U22A20280);
545 Science & Technology Department of Sichuan Province (2023NSFSC1607,
546 2021YFSY0003, 2022YFS0051, 2022NSFSC1312); Shenzhen-HongKong Institute of
547 Brain Science-Shenzhen Fundamental Research Institutions (312200102); Clinical
548

549 Research Incubation project of West China Hospital of Sichuan University
550 (2021HXFH036).

551

552 **Author contributions**

553 HD conceived the project, designed and performed the experiments, analyzed the data,
554 and wrote the manuscript. YZhang co-conceived the project, did all the bioinformatics
555 analysis and prepared figures. XYu and DW performed cell isolations. XYou performed
556 immunofluorescence microscopy and helped with Cut&Tag. ZLuo and YC performed
557 animal experiments. HL and ZLiao participated in clinical sample acquisition. B-SD,
558 YZhao and YW provided suggestions and revised the manuscript. KX drew part of the
559 working model. FY, FG, NN and JZ revised the manuscript. ZZ and SH supervised the
560 work and revised the manuscript.

561 **Disclosure and competing interests statement**

562 The authors declare that they have no conflict of interest.

563

564

565 **References**

- 566 Agger K, Cloos PAC, Christensen J, Pasini D, Rose S, Rappsilber J, Issaeva I, Canaani E,
567 Salcini AE & Helin K (2007) UTX and JMJD3 are histone H3K27 demethylases
568 involved in HOX gene regulation and development. *Nature* 449: 731–734
- 569 Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus
570 VB, Lohmander LS, Abbott JH, Bhandari M, *et al* (2019) OARSI guidelines for the non-
571 surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis and*
572 *Cartilage* 27: 1578–1589
- 573 Camilleri ET, Dudakovic A, Riester SM, Galeano-Garces C, Paradise CR, Bradley EW,
574 McGee-Lawrence ME, Im H-J, Karperien M, Krych AJ, *et al* (2018) Loss of histone
575 methyltransferase Ezh2 stimulates an osteogenic transcriptional program in
576 chondrocytes but does not affect cartilage development. *Journal of Biological Chemistry*
577 293: 19001–19011
- 578 Dai J, Yu D, Wang Y, Chen Y, Sun H, Zhang X, Zhu S, Pan Z, Heng BC, Zhang S, *et al* (2017)
579 Kdm6b regulates cartilage development and homeostasis through anabolic metabolism.
580 *Ann Rheum Dis* 76: 1295–1303
- 581 De Santa F, Narang V, Yap ZH, Tusi BK, Burgold T, Austenaa L, Bucci G, Caganova M,
582 Notarbartolo S, Casola S, *et al* (2009) Jmjd3 contributes to the control of gene
583 expression in LPS-activated macrophages. *EMBO J* 28: 3341–3352
- 584 De Santa F, Totaro MG, Prosperini E, Notarbartolo S, Testa G & Natoli G (2007) The Histone
585 H3 Lysine-27 Demethylase Jmjd3 Links Inflammation to Inhibition of Polycomb-
586 Mediated Gene Silencing. *Cell* 130: 1083–1094
- 587 Du X, Chen Y, Zhang Q, Lin J, Yu Y, Pan Z, Sun H, Yuan C, Yu D, Wu H, *et al* (2020) *Ezh2*
588 Ameliorates Osteoarthritis by Activating TNFSF13B. *J Bone Miner Res* 35: 956–965
- 589 Dudakovic A, Camilleri ET, Xu F, Riester SM, McGee-Lawrence ME, Bradley EW, Paradise
590 CR, Lewallen EA, Thaler R, Deyle DR, *et al* (2015) Epigenetic Control of Skeletal

- 591 Development by the Histone Methyltransferase Ezh2. *Journal of Biological Chemistry*
592 290: 27604–27617
- 593 Ernst J & Kellis M (2012) ChromHMM: automating chromatin-state discovery and
594 characterization. *Nat Methods* 9: 215–216
- 595 Ernst J & Kellis M (2017) Chromatin-state discovery and genome annotation with
596 ChromHMM. *Nat Protoc* 12: 2478–2492
- 597 Estarás C, Akizu N, García A, Beltrán S, de la Cruz X & Martínez-Balbás MA (2012) Genome-
598 wide analysis reveals that Smad3 and JMJD3 HDM co-activate the neural
599 developmental program. *Development* 139: 2681–2691
- 600 Grandi FC & Bhutani N (2020) Epigenetic Therapies for Osteoarthritis. *Trends in*
601 *Pharmacological Sciences* 41: 557–569
- 602 Hong S, Cho Y-W, Yu L-R, Yu H, Veenstra TD & Ge K (2007) Identification of JmjC domain-
603 containing UTX and JMJD3 as histone H3 lysine 27 demethylases. *Proc Natl Acad Sci*
604 *U S A* 104: 18439–18444
- 605 Hyun K, Jeon J, Park K & Kim J (2017) Writing, erasing and reading histone lysine
606 methylations. *Exp Mol Med* 49: e324–e324
- 607 Jun Z, Xinmeng J, Yue L, Zhi W, Yan Z, Tieyi Y & Jiangan T (2020) Jumonji domain
608 containing-3 (JMJD3) inhibition attenuates IL-1 β -induced chondrocytes damage in vitro
609 and protects osteoarthritis cartilage in vivo. *Inflamm Res* 69: 657–666
- 610 Karsdal MA, Michaelis M, Ladel C, Siebuhr AS, Bihlet AR, Andersen JR, Guehring H,
611 Christiansen C, Bay-Jensen AC & Kraus VB (2016) Disease-modifying treatments for
612 osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and
613 opportunities for the future. *Osteoarthritis Cartilage* 24: 2013–2021
- 614 Kaya-Okur HS, Janssens DH, Henikoff JG, Ahmad K & Henikoff S (2020) Efficient low-cost
615 chromatin profiling with CUT&Tag. *Nat Protoc* 15: 3264–3283
- 616 Kruidenier L, Chung C, Cheng Z, Liddle J, Che K, Joberty G, Bantscheff M, Bountra C,
617 Bridges A, Diallo H, *et al* (2012) A selective jumonji H3K27 demethylase inhibitor
618 modulates the proinflammatory macrophage response. *Nature* 488: 404–408
- 619 Ling C & Rönn T (2019) Epigenetics in Human Obesity and Type 2 Diabetes. *Cell Metabolism*
620 29: 1028–1044
- 621 Meers MP, Tenenbaum D & Henikoff S (2019) Peak calling by Sparse Enrichment Analysis for
622 CUT&RUN chromatin profiling. *Epigenetics & Chromatin* 12: 42
- 623 Millán-Zambrano G, Burton A, Bannister AJ & Schneider R (2022) Histone post-translational
624 modifications — cause and consequence of genome function. *Nat Rev Genet* 23: 563–
625 580

- 626 Mirzamohammadi F, Papaioannou G, Inloes JB, Rankin EB, Xie H, Schipani E, Orkin SH &
627 Kobayashi T (2016) Polycomb repressive complex 2 regulates skeletal growth by
628 suppressing Wnt and TGF- β signalling. *Nat Commun* 7: 12047
- 629 Monteagudo S, Cornelis FMF, Aznar-Lopez C, Yibmantasiri P, Guns L-A, Carmeliet P,
630 Cailotto F & Lories RJ (2017) DOT1L safeguards cartilage homeostasis and protects
631 against osteoarthritis. *Nat Commun* 8: 15889
- 632 Pitsillides AA & Beier F (2011) Cartilage biology in osteoarthritis—lessons from
633 developmental biology. *Nat Rev Rheumatol* 7: 654–663
- 634 Ramírez F, Ryan DP, Grüning B, Bhardwaj V, Kilpert F, Richter AS, Heyne S, Dündar F &
635 Manke T (2016) deepTools2: a next generation web server for deep-sequencing data
636 analysis. *Nucleic Acids Research* 44: W160–W165
- 637 Reynard LN (2017) Analysis of genetics and DNA methylation in osteoarthritis: What have we
638 learnt about the disease? *Seminars in Cell & Developmental Biology* 62: 57–66
- 639 Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T & Chang W (2022)
640 DAVID: a web server for functional enrichment analysis and functional annotation of
641 gene lists (2021 update). *Nucleic Acids Res* 50: W216-221
- 642 Smeriglio P, Grandi FC, Davala S, Masarapu V, Indelli PF, Goodman SB & Bhutani N (2020)
643 Inhibition of TET1 prevents the development of osteoarthritis and reveals the 5hmC
644 landscape that orchestrates pathogenesis. *Sci Transl Med* 12: eaax2332
- 645 Taylor SEB, Li YH, Wong WH & Bhutani N (2015) Genome-Wide Mapping of DNA
646 Hydroxymethylation in Osteoarthritic Chondrocytes: DYNAMICS OF 5hmC IN OA.
647 *Arthritis & Rheumatology* 67: 2129–2140
- 648 Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdulle
649 AM, Abebo TA, Abera SF, *et al* (2017) Global, regional, and national incidence,
650 prevalence, and years lived with disability for 328 diseases and injuries for 195
651 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study
652 2016. *The Lancet* 390: 1211–1259
- 653 Wuelling M, Neu C, Thiesen AM, Kitanovski S, Cao Y, Lange A, Westendorf AM, Hoffmann
654 D & Vortkamp A (2021) Epigenetic Mechanisms Mediating Cell State Transitions in
655 Chondrocytes. *J Bone Miner Res* 36: 968–985
- 656 Xiang Y, Zhu Z, Han G, Lin H, Xu L & Chen CD (2007) JMJD3 is a histone H3K27
657 demethylase. *Cell Res* 17: 850–857
- 658 Yang J-H, Hayano M, Griffin P, Amorim JA, Bonkowski MS, Apostolides JK, Blanchette M,
659 Munding EM, Bhakta M, Salfati EL, *et al* (2021) Loss of Epigenetic Information as a
660 Cause of Mammalian Aging. *SSRN Journal*
- 661 Yapp C, Carr AJ, Price A, Oppermann U & Snelling SJB (2016) H3K27me3 demethylases
662 regulate in vitro chondrogenesis and chondrocyte activity in osteoarthritis. *Arthritis Res*
663 *Ther* 18: 158

664 Zhang F, Xu L, Xu L, Xu Q, Li D, Yang Y, Karsenty G & Chen CD (2015) JMJD3 promotes
665 chondrocyte proliferation and hypertrophy during endochondral bone formation in mice.
666 *Journal of Molecular Cell Biology* 7: 23–34

667 Zhang W, Qu J, Liu G-H & Belmonte JCI (2020) The ageing epigenome and its rejuvenation.
668 *Nat Rev Mol Cell Biol* 21: 137–150

669
670
671
672
673
674

Figure legends

675 **Figure 1. Histone modification profiling of normal and OA chondrocytes.**

- 676 (A) Schematic diagram of the experimental design. Chondrocytes from Normal (n=3), OA
677 (n=5), OA-Intact and OA-Damaged (Paired, n=2) samples were used for CUT&Tag and
678 RNA-seq.
- 679 (B) Tag density of each histone mark across the gene bodies (+/-5kb) in Normal and OA (left),
680 paired OA-intact and OA-damaged (right).
- 681 (C) Genome-wide peak distribution of each modification in Normal, OA, OA-intact and OA-
682 damaged samples. The numbers of peaks in promoter, gene body, enhancer, 10kb nearby
683 gene body, and intergenic regions are shown.
- 684 (D) The numbers of differential modified genes ($\log_2FC > 0.58$, $p\text{-value} < 0.05$) between Normal
685 and OA, OA-intact and OA-damaged for each histone mark.
- 686 (E) Venn diagram of genes which lose H3K27me3 in OA vs. Normal and OA-Damaged vs.
687 OA-Intact.
- 688 (F) Tag density and heatmap of H3K27me3 across the gene bodies (+/-5kb) of genes which loss
689 H3K27me3 in OA vs. Normal, OA-Damaged vs. OA-Intact and both.
- 690 (G) The numbers of differential peaks outside genes ($\log_2FC > 0.58$, $p\text{-value} < 0.05$) between
691 Normal and OA, OA-intact and OA-damaged for each histone mark.
- 692 (H) Distribution of up-regulated peaks outside genes for H3K4me3 and H3K27me3 in OA vs.
693 Normal.

694

695 **Figure 2. Correlation between histone modification and differential gene expression.**

- 696 (A) Heatmap of differential gene expression ($\log_2FC > 0.58$) between Normal and OA, OA-
697 intact and OA-damaged.
- 698 (B) Correlation between each histone modification and gene expression in normal chondrocytes.
699 Genes were grouped to 100 gene (one dot in the online supplemental figure) sets according
700 to each histone modification level.
- 701 (C) Pearson correlation between changes in histone modification and gene expression for OA
702 vs. Normal and OA-Damaged vs. OA-Intact. The fold changes in both expression level and
703 histone modification level were calculated for each gene. The genes were grouped into 100
704 gene sets according to their histone modification changes.

705 (D) Tag density of H3K27me3, H3K4me3 and H3K27ac across the gene bodies (+/-5kb) of
706 genes up-regulated or down-regulated expression in OA vs. Normal and OA-Damaged vs.
707 OA-Intact.

708 (E) Venn diagram of genes which lose H3K27me3 and gain expression in OA vs. Normal and
709 OA-Damaged vs. OA-Intact.

710 (F) GO terms with the highest enrichment of 128 genes which lose H3K27me3 and gain
711 expression in both OA vs. Normal and OA-Damaged vs. OA-Intact.

712

713 **Figure 3. H3K27me3 loss in bivalent promoters up-regulate gene expression in OA.**

714 (A) Chromatin state definitions (emission probabilities) of a 12-state ChromHMM model based
715 on the Normal, OA, OA-intact and OA-damaged data sets.

716 (B) Promoter state define of all genes in each Normal and OA sample by the chromatin states of
717 2kb region around TSS.

718 (C) Promoter state distribution of genes that lose H3K27me3 in OA vs. Normal.

719 (D) Box plot showing the H3K27me3 changes of genes that lose H3K27me3 in OA vs. Normal
720 with promoter state 5-8 in Normal. The significance of difference among all states was
721 calculated by ANOVA test, and the significance of difference between state 8 and other
722 states was determined by two side t test.

723 (E) Box plot showing the RNA expression changes of genes that lose H3K27me3 in OA vs.
724 Normal with promoter state 5-8 in Normal.

725 (F) Promoter state distribution of up-regulated genes in OA vs. Normal.

726 (G) Promoter state transitions of all genes from normal to OA. The transition ratio was
727 normalized by the count of genes of each state in Normal.

728 (H) Heatmap showing the K4/K27 bivalent promoters in normal samples and their state changes
729 in OA, OA-Intact and OA-Damaged samples.

730 (I) GO terms with the highest enrichment of bivalent genes which lose H3K27me3 in OA and
731 their enrichment score of bivalent genes that lose H3K27me3 during endochondral
732 ossification.

733 (J) Dot plot showing the expression level of bivalent genes lose either H3K27me3 or H3K4me3
734 in OA vs Normal (up) and OA-Damaged vs OA-Intact (down).

735 (K) Box/Violin plot showing the expression changes of bivalent genes lose either H3K27me3 or
736 H3K4me3 in OA vs Normal (left) and OA-Damaged vs OA-Intact (right).

737 (L) Examples of bivalent genes which lose H3K27me3 and gain expression during the
738 progression of OA.

739

740 **Figure 4. Inflammation induced H3K27 demethylase expression in OA chondrocytes.**

741 (A) The RNA expression level of H3K27me3 methylases and demethylases in paired control
742 and IL-1 β treated human chondrocytes from OA patients (n=3 for EZH1, n=5 for others).
743 Data were analyzed by two-tailed ratio paired t test.

744 (B) Immunofluorescence for KDM6B in human normal and OA cartilage.

- 745 (C) Quantification of KDM6B-positive cells in human normal (n=3) and OA (n=9) samples.
746 Data were analyzed by two-tailed unpaired t test and are shown as means \pm SD.
- 747 (D) The RNA expression level of KDM6B during a time course of IL-1 β addition and removal.
748 The same sample was measured repeatedly (n=3). Data were analyzed by ordinary one-way
749 ANOVA followed by Tukey's multiple comparisons test and are shown as means \pm SD.
- 750 (E) H&E staining for synovium and immunofluorescence for KDM6B in rat ACLT- DMM OA
751 models.
- 752 (F) Quantification of KDM6B-positive cells in rat control (n=3) and OA (n=3) samples. Data
753 were analyzed by ordinary one-way ANOVA followed by Tukey's multiple comparisons test
754 and are shown as means \pm SD. **P < 0.01, ***P < 0.001.

755

756 **Figure 5. Demethylase inhibitor rescued inflammation induced H3K27me3 loss and**
757 **abnormal gene expression.**

- 758 (A) Tag density of H3K27me3 across the gene bodies (+/-5kb) genome-wide in human OA
759 chondrocytes during a time course of IL-1 β addition and removal.
- 760 (B) Tag density of H3K27me3 across the gene bodies (+/-5kb) genome-wide in human OA
761 chondrocytes treated with IL-1 β and GSK-J4 (GJ4).
- 762 (C) Venn diagram of genes which lose H3K27me3 upon IL-1 β treatment and restored
763 H3K27me3 by GSK-J4 and genes loss H3K27me3 in OA samples.
- 764 (D) H3K27me3 tag density of the overlapped 569 genes (left) and the other 3092 genes (right)
765 in Fig 3C.
- 766 (E) Examples of H3K27me3 distributions around genes which lose H3K27me3 upon IL-1 β
767 treatment and restored H3K27me3 by GSK-J4.
- 768 (F) Relative expression of genes which lose H3K27me3 upon IL-1 β treatment and restored
769 H3K27me3 by GSK-J4. The same sample was measured repeatedly (n=3). Data were
770 analyzed by ordinary one-way ANOVA and are shown as means \pm SD. *P < 0.05; **P <
771 0.01; ***P < 0.001; ****P < 0.0001.

772

773 **Figure 6. Working model: Inflammation induced epigenetic activation of bivalent genes in**
774 **osteoarthritic cartilage.**

775 During the osteogenesis of growth plate cartilage, hypertrophy related genes were occupied by
776 both H3K27me3 and H3K4me3 due to the need for rapid activation. However, in its
777 homologous articular chondrocytes, hypertrophic genes remained in a bivalent state. In
778 normal conditions, these bivalent genes maintain transcriptional inhibition; In OA,
779 inflammatory cytokines such as IL-1 β induce the expression of H3K27me3 demethylase
780 KDM6B to remove H3K27me3 thus facilitate the expression of hypertrophic genes, which
781 promote the degradation of cartilage matrix and leads to OA.

782

783

784

785

Expanded View Figure legends

786 **Figure EV1. Histone modification profiling of each normal and OA sample.**

- 787 (A) Safranin O-Fast Green staining of human femoral condylar cartilage used for histone
788 modification profiling.
- 789 (B) Tag density of each histone mark across the gene bodies (+/-5kb) in each Normal and OA
790 samples.
- 791 (C) Genome-wide peak distribution of each modification in each sample. The numbers of peaks
792 in promoter, gene body, enhancer, 10kb nearby gene body, and intergenic regions are
793 shown.
- 794 (D) Correlation map of each sample for the four histone marks.

795 **Figure EV2. Differences of H3K4me3 and H3K27me3 in normal and OA.**

- 796 (A) Venn diagram of genes which lose H3K4me3 in OA vs. Normal and OA-Damaged vs. OA-
797 Intact.
- 798 (B) Tag density and heatmap of H3K4me3 across the gene bodies (+/-5kb) of genes which loss
799 H3K4me3 in OA vs. Normal, OA-Damaged vs. OA-Intact and both.
- 800 (C) Chromosome distribution of up-regulated H3K4me3 peaks outside genes in OA vs. Normal
801 and Dam vs. Int respectively.
- 802 (D) Chromosome distribution of up-regulated H3K27me3 peaks outside genes in OA vs.
803 Normal and Dam vs. Int respectively.

804 **Figure EV3. Correlation map of each sample for the four histone marks.**

805 **Figure EV4. ChromHMM analysis of human and mice datasets.**

- 806 (A) Enrichment scores for chromatin states in genomic features for 3 normal samples. The first
807 column shows the genome-wide percentage of occupancy for each state. Subsequent
808 columns show enrichments for CpG islands, Refseq annotated exons, genes, transcription
809 ends sites (TES), transcription start sites (TSS) and TSS + -2 kb regions. Each column is
810 colored from 0 (white) to its maximum value (blue).
- 811 (B) Heatmap showing the state agreement between Normal, OA, OA-Int and OA-Dam subsets.
- 812 (C) Chromatin state definitions (emission probabilities) of a 12-state ChromHMM model based
813 on the mouse PC/HC data sets.
- 814 (D) The count of genomic bins in each state in mouse PC/HC data sets. (E) State transitions
815 from PC to HC.

816 **Figure EV5. The expression of H3K27 methylation regulators in RNA-seq data from 4**
817 **groups.**

818
819
820 **Table EV1. Quality control of CUT&Tag libraries.**

821 **Table EV2. Quality control of RNA-seq.**

822 **Table EV3. Bivalent genes in mouse proliferating chondrocytes that lost H3K27me3 in**
823 **hypertrophic chondrocytes.**

Figure 1 | Histone modification profiling of normal and OA chondrocytes.




Figure 2 | Correlation between histone modification and differential gene expression.





Figure 3 | H3K27me3 loss in bivalent promoters up-regulate gene expression in OA.



medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 4 | Inflammation induced H3K27 demethylase expression in OA chondrocytes.




Figure 5 | Demethylase inhibitor rescued inflammation induced H3K27me3 loss and abnormal gene expression




Figure 6. Working model: Inflammation induced epigenetic activation of bivalent genes in osteoarthritic cartilage

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure EV1. Histone modification profiling of each normal and OA sample

A medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



B



C






Figure EV2. Differences of H3K4me3 and H3K27me3 in normal and OA


medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

A



C

H3K4me3



D

H3K27me3




Figure EV3. Correlation map of each sample for the four histone marks

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







Figure EV4. ChromHMM analysis of human and mice datasets

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


A



C



D



E




Figure EV5. The expression of H3K27 methylation regulators in RNA-seq data from 4 groups

medRxiv preprint doi: <https://doi.org/10.1101/2023.04.13.23288509>; this version posted April 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

